Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 250 entries
View as:

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Phase: N/A Priority: Normal
NCT ID: NCT07034508 Org: User:
Start: 06/20/25 End: 12/20/29 Due: 12/20/30

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Phase: N/A Priority: Normal
NCT ID: NCT06254560 Org: User:
Start: 02/23/23 End: 12/30/27 Due: 12/30/28

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06464185 Org: User:
Start: 04/30/24 End: 04/30/27 Due: 04/30/28

Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06608342 Org: User:
Start: 06/25/24 End: 05/30/28 Due: 05/30/29

Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

Phase: N/A Priority: Normal
NCT ID: NCT06525519 Org: User:
Start: 07/31/24 End: 07/31/26 Due: 07/31/27

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05979363 Org: User:
Start: 07/01/23 End: 07/01/28 Due: 07/01/29

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Phase: N/A Priority: Normal
NCT ID: NCT05395507 Org: User:
Start: 06/01/22 End: 06/30/25 Due: 06/30/26

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Phase: N/A Priority: Normal
NCT ID: NCT05603156 Org: User:
Start: 10/30/22 End: 07/31/24 Due: 07/31/25

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06415708 Org: User:
Start: 11/30/23 End: 06/30/26 Due: 06/30/27

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT06530550 Org: User:
Start: 08/10/24 End: 07/10/28 Due: 07/10/29

A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP

Phase: N/A Priority: Normal
NCT ID: NCT06658834 Org: User:
Start: 06/01/24 End: 08/30/26 Due: 08/30/27

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria

Phase: N/A Priority: Normal
NCT ID: NCT01642979 Org: User:
Start: 07/31/12 End: 07/31/17 Due: 07/31/18

Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06921980 Org: User:
Start: 02/25/25 End: 12/31/26 Due: 12/31/27

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT05718856 Org: User:
Start: 02/23/23 End: 11/14/25 Due: 11/14/26

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06386302 Org: User:
Start: 08/05/24 End: 12/30/27 Due: 12/30/28

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Phase: N/A Priority: Normal
NCT ID: NCT06481228 Org: User:
Start: 06/04/24 End: 06/01/28 Due: 06/01/29

Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT05832216 Org: User:
Start: 04/17/23 End: 12/01/24 Due: 12/01/25

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

Phase: N/A Priority: Normal
NCT ID: NCT03664518 Org: User:
Start: 12/04/18 End: 09/30/22 Due: 09/30/23

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Phase: N/A Priority: Normal
NCT ID: NCT04915482 Org: User:
Start: 06/06/21 End: 02/28/25 Due: 02/28/26

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

Phase: N/A Priority: Normal
NCT ID: NCT06102694 Org: User:
Start: 11/16/23 End: 12/31/25 Due: 12/31/26

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Phase: N/A Priority: Normal
NCT ID: NCT05860595 Org: User:
Start: 05/23/23 End: 10/24/25 Due: 10/24/26

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT06287567 Org: User:
Start: 04/17/24 End: 11/30/24 Due: 11/30/25

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Phase: N/A Priority: Normal
NCT ID: NCT05361057 Org: User:
Start: 05/01/22 End: 08/31/23 Due: 08/31/24

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT06087419 Org: User:
Start: 10/30/23 End: 12/30/25 Due: 12/30/26

BCMA CAR-T for Dynamic High-risk Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06880393 Org: User:
Start: 03/31/25 End: 01/31/28 Due: 01/31/29